血清VEGF水平与儿童青少年非霍奇金淋巴瘤的临床关系初步探讨

Primary Study of Relationship between Serum Level of VEGF and Non-Hodgkin's Lymphoma in Children and Adolescent Patients

背景与目的:血管新生机制是恶性肿瘤的重要发病机制之一,血管内皮生长因子(vascularendothelialgrowthfactor,VEGF)是其中的关键因素,本研究拟探讨血清VEGF(sVEGF)水平与儿童、青少年非霍奇金淋巴瘤(non-Hodgkinslymphoma,NHL)的临床关系。方法:使用ELISA法对24例3～20岁NHL患者初诊时的sVEGF水平进行检测,并对其中经化疗获得完全缓解的10例患者治疗前后的sVEGF水平进行比较。结果:24例初诊NHL患者的sVEGF浓度为40.64～3623.09ng/L(平均浓度745.79ng/L,中位浓度497.78ng/L),其中18例sVEGF水平高于正常对照值(294.20±23.40ng/L),占所有病例的75%,6例sVEGF处于正常范围内,占所有病例25%。10例治疗后获得首次缓解的患者sVEGF水平为35.11～826.8ng/L(平均浓度为289.54ng/L,中位浓度为213.54ng/L),其中8例患者治疗前sVEGF水平较高而治疗后sVEGF水平较治疗前明显下降,2例治疗前后sVEGF水平均在正常范围内。结论:青少年儿童NHL患者的sVEGF水平高于正常人群;经治疗获得缓解的NHL患儿sVEGF水平呈下降趋势;本研究尚未发现sVEGF与NHL患儿临床分期、B症状、年龄、性别、IPI评分、血清LDH等临床指标有显著性相关。

BACKGROUND &OBJECTIVE:Angiogenesis is an important mechanism in mo rbility of malignant tumor,vascular endothelial growth factor (VEGF) is the key factor. This study was to investigate the serum level of VEGF in children and ad olescent patients with non-Hodgkins lymphoma (NHL). METHODS: The serum leve ls of VEGF(sVEGF)in 24 pretreated NHL patients were detected by ELISA. sVEGF i n 10 of the 24 patients who received complete response after treatment were also detected by ELISA. RESULTS: The average serum VEGF level was 745.79 ng/L (40.64-3623.09 ng/L)in 24 NHL patients.It was higher than normal [(294.20±23.40)ng/ L]. sVEGF in 18 of the patients were higher than the standard, while in 6 of th e patients were lower than the standard. The average serum VEGF level was 289.54 n g/L(35.11-826.8 ng/L) in 10 of The CR patients, 8 cases of them had a high VEGF level before treatment but a nearly normal level after first CR.And 2 cases of them had normal level during the course. CONCLUSIONS: The serum level of VEGF in NHL patients was higher than normals. The high serum level of VEGF has a tenden cy to drop to the normal standard after receiving CR.From the clinical data, a h igh serum level was not found associated with stage, gender, PS. score,IPI score , serum LDH and “B”symptoms et al.